Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31

被引：110

作者：

Agger, Else Marie

Rosenkrands, Ida

Olsen, Anja Weinreich

Hatch, Graham

Williams, Ann

Kritsch, Constantia

Lingnau, Karen

von Gabain, Alexander

Andersen, Claire Swetman

Korsholm, Karen Smith

Andersen, Peter

机构：

[1] Statens Serum Inst, Dept Infect Dis Immunol, Adjuvant Res, DK-2300 Copenhagen S, Denmark

[2] Hlth Protect Agcy, Ctr Emergency Preparedness & Response, Salisbury SP4 0JG, Wilts, England

[3] Intercell AG, A-1030 Vienna, Austria

来源：

VACCINE | 2006年 / 24卷 / 26期

关键词：

tuberculosis; vaccine; adjuvant;

D O I：

10.1016/j.vaccine.2006.03.072

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this study, we evaluated the potential of a novel synthetic adjuvant designated 101 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic peptide KLKL5KLK and the immunostimulatory oligodeoxynucleotide ODN1a signalling through the TLR9 receptor, was found to promote highly efficient Th1 responses. The combination of Ag85B-ESAT-6 and IC31 exhibited significant levels of protection in the mouse aerosol challenge model of tuberculosis and a detailed analysis of the immune response generated revealed the induction of CD4 T cells giving rise to high levels of IFN-gamma secretion. Furthermore, the combination of Ag85B-ESAT-6/IC31 was found to confer efficient protection in the guinea pig aerosol model of tuberculosis infection and is at present moving towards clinical testing. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：5452 / 5460

页数：9

共 35 条

[11] The physiology and pathogenicity of Mycobacterium tuberculosis grown under controlled conditions in a defined medium
James, BW
Williams, A
Marsh, PD
[J]. JOURNAL OF APPLIED MICROBIOLOGY, 2000, 88 (04) : 669 - 677
[12] Jarrossay D, 2001, EUR J IMMUNOL, V31, P3388, DOI 10.1002/1521-4141(200111)31:11<3388::AID-IMMU3388>3.0.CO
[13] 2-Q
[14] Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens
Kadowaki, N
Ho, S
Antonenko, S
Malefyt, RD
Kastelein, RA
Bazan, F
Liu, YJ
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (06) : 863 - 869
[15] Separation and quantification of a novel two-component vaccine adjuvant
Kritsch, CE
Berger, A
Heinrich-Cseh, C
Bugajska-Schretter, A
Zauner, W
[J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 822 (1-2): : 263 - 270
[16] Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6
Langermans, JAM
Doherty, TM
Vervenne, RAW
van der Laan, T
Lyashchenko, K
Greenwald, R
Agger, EM
Aagaard, C
Weiler, H
van Soolingen, D
Dalemans, W
Thomas, AW
Andersen, P
[J]. VACCINE, 2005, 23 (21) : 2740 - 2750
[17] Adjuvant modulation of immune responses to tuberculosis subunit vaccines
Lindblad, EB
Elhay, MJ
Silva, R
Appelberg, R
Andersen, P
[J]. INFECTION AND IMMUNITY, 1997, 65 (02) : 623 - 629
[18] Is IgG2a a good Th1 marker in mice?
Martin, RM
Lew, AM
[J]. IMMUNOLOGY TODAY, 1998, 19 (01): : 49 - 49
[19] Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO
[20] 2-Z

← 1 2 3 4 →